Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2013

01-08-2013 | Erratum

Erratum to: Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis—correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met

Authors: Alexandros Garouniatis, Adamantia Zizi-Sermpetzoglou, Spyros Rizos, Alkiviadis Kostakis, Nikolaos Nikiteas, Athanasios G. Papavassiliou

Published in: Tumor Biology | Issue 4/2013

Login to get access

Excerpt

Erratum to: Tumor Biology …
Metadata
Title
Erratum to: Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis—correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met
Authors
Alexandros Garouniatis
Adamantia Zizi-Sermpetzoglou
Spyros Rizos
Alkiviadis Kostakis
Nikolaos Nikiteas
Athanasios G. Papavassiliou
Publication date
01-08-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0918-5

Other articles of this Issue 4/2013

Tumor Biology 4/2013 Go to the issue

Research Article

Associations of CYP2E1 rs2031920 and rs3813867 polymorphisms with colorectal cancer risk: a systemic review and meta-analysis

Research Article

Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012

Research Article

A common gene variant in PLS3 predicts colon cancer recurrence in women

Research Article

microRNAs in uterine sarcomas and mixed epithelial–mesenchymal uterine tumors: a preliminary report

Research Article

Mitochondrial D310 instability in Asian Indian breast cancer patients

Research Article

XRCC1 Arg194Trp polymorphism is associated with oral cancer risk: evidence from a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits